• Richard Staines
• 08 Jan, 2019

Barrett raised eyebrows last month when she announced her decision to leave Novartis after less than a year in charge of its oncology unit, but kept quiet about her new job. Now New York-based UroGen has revealed it has pulled off a coup and hired Barrett, an industry veteran with a proven track record launching cancer drugs. UroGen in November began a rolling filing of data from its UGN-101, a treatment for low-grade upper tract urothelial cancer.
Read more...